Lipocine has dosed the first participant in BLOOM, their phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression.
Related to this article
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Preventing Schizophrenia Relapse in Women: What You Need to Know
2
Scams: What Psychiatrists Need to Know
3
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
4
A Veterans Day Salute: Lessons From 1918 and 2026 for Psychiatrists
5